Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
PBMs: Merck-Medco in the Hot Seat
Author(s)Andra Brichacek
Franklin Lakes, New Jersey-Merck’s pharmacy benefit arm, Merck-Medco, is under fire for switching patients to more expensive pharmaceuticals.
Advertisement
Articles in this issue
about 25 years ago
National Crisis Supercedes Coverage Debateabout 25 years ago
National Crisis Supercedes Coverage Debateabout 25 years ago
A Five-Year Forecast: Clear Seas Ahead?about 25 years ago
Weak Bones, Strong Marketabout 25 years ago
Approvals: Novartis’ Silver Liningabout 25 years ago
Pfizer and others Pitch Inabout 25 years ago
Oncology: EMEA Approval Lagsabout 25 years ago
Illegal Sales in Indiaabout 25 years ago
Health Plan Premiums: Pharma Takes the Blameabout 25 years ago
Little Elan Becomes a Big DealAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
4
Closing the Pediatric Evidence Gap
5